| Identification | Back Directory | [Name]
5-[3-[1-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propanoate | [CAS]
64228-79-1 | [Synonyms]
Atracurium
ATRACURIUM BESYLATE
AtracuriuM Besylate USP/EP/BP
Atracurium Impurity 2（Trans - single -
Atracurium for peak identification CRS
5-[3-[1-[(3,4-DiMethoxyphenyl)Methyl]-6,7-diMethoxy-2-Methyl-3,4-dihydro-1H-isoquinolin-2-yl]propano
2,2'-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium]
2,2'-[Pentane-1,5-diylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolin-2-ium]
5-[3-[1-[(3,4-Dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]propanoate | [EINECS(EC#)]
264-743-4 | [Molecular Formula]
C53H72N2O12 | [MDL Number]
MFCD00869583 | [MOL File]
64228-79-1.mol | [Molecular Weight]
929.14 |
| Chemical Properties | Back Directory | [Melting point ]
185-194 ºC | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Chemical Properties]
Atracurium besylate is a white to yellow-white powder with slight hygroscopicity. It is soluble in water and very soluble in ethanol, acetonitrile and dichloromethane. It contains three isomers: cis-cis, cis-trans and trans-trans. | [Uses]
Atracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category ofnon-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesiato facilitate endotracheal intubation and to provide skeletal muscle relaxationduring surgery or mechanical ventilation.The drug atracurium besylate can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored. | [Definition]
ChEBI: A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. | [Hazard]
Extremely toxic. | [Pharmacokinetics]
Atracurium besylate, a new non-depolarizing neuromuscular blocking agent, with short to intermediary duration of action and no significant cardiovascular effects. Not dependent on kidney function for elimination, it provides clinical advantages over other non-depolarizing, neuromuscular blocking agents. In vitro, in human plasma, the half-life of the drug was similar to that in buffer at the same pH being approximately 25 min (Hughes and Chappie, 1980). | [Synthesis]
Atracurium is 2,2-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]] bis
[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolinium]
dibenzene sulfonate (15.1.12). This compound is synthesized from bis-acrylic
ester of 1,5-pentandiol (15.1.10), which is synthesized from acrylic acid chloride and 1,
5-pentandiol. Two molecules of a secondary amine, tetrahydropapaverine, are joined to the
product in a Michael reaction, forming compound (15.1.11). Then both nitrogen atoms are
methylated by methylbenzenesulfonate, giving atracurium (15.1.12).
| [Metabolism]
Atracurium besylate is a nondepolarizing neuromuscular blocker in which the quaternary ammonium groups are located in two substituted
tetrahydroisoquinoline rings separated by an aliphatic diester. It has a duration of action slightly longer than that of succinylcholine. Atracurium
is not metabolized in the liver; rather, it undergoes hydrolysis of the ester functional groups that connect the two quaternary nitrogens. It also
undergoes Hofmann elimination, a nonenzymatic, base-catalyzed decomposition, to yield laudanosine, which is inactive.
T hus, termination of the effects of atracurium are independent of renal elimination. Because of this unusual metabolic profile, it is useful in
patients with hepatic or renal disease. |
|
|